The presymptomatic treatment with 3HFWC nanosubstance decreased plaque load in 5XFAD mouse model of Alzheimer's disease.

Milka PerovicJelena CiricValentina MatovicMaja SrbovanDjuro KorugaSelma KanazirSanja Ivkovic

Published in: CNS neuroscience & therapeutics (2023)

The obtained results point to the potential of 3HFWC, when applied in the presymptomatic phase of AD, to interfere with amyloid plaque formation without inducing AD-related pathological processes such as neuroinflammation, gliosis, and synaptic vulnerability.

Keyphrases

mouse model
coronary artery disease
climate change
traumatic brain injury
lipopolysaccharide induced
cognitive impairment
risk assessment
lps induced
combination therapy
replacement therapy
human health